AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11309872
Drug: Inhalation sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation sedation (IHS)
Trial: 9343033
Drug: Oral propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone (600 mg loading dose)
Trial: 8201510
Drug: Modified bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified bovine lung surfactant extract (beractant), 4 doses
Trial: 2906778
Drug: Lormetazepam (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (sublingual administration)
Trial: 28972663
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (DLPDT)
Trial: 28972663
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (CPDT)
Trial: 27547851
Drug: G1 (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1 (twice a week plyometric training)
Trial: 27547851
Drug: G2 (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2 (twice a week plyometric training)
Trial: 25062570
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral nutritional supplements
Trial: 25062570
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment with water or lemonade
Trial: 3912186
Drug: Bambuterol 30
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol 30 mg administered once daily before going to bed
Trial: 3912186
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release terbutaline 10 mg twice daily
Trial: 3912186
Drug: Bambuterol 30
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol 30 mg administered once daily
Trial: 29144535
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control (WLC) with unrestricted access to treatment as usual
Trial: 27421672
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: intravenous administration of contrast material at a dose of 1mL/kg and CTA examinations at 100kV
Trial: 27421672
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: intravenous administration of contrast material at a dose of 0.5mL/kg and CTA examinations at 80kV
Trial: 24045855
Drug: Protein drink
RxNorm normalized name: Boost High Protein Drink, Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein drink containing 15 g protein, twice a day
Trial: 24045855
Drug: Placebo drink,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink, twice a day
Trial: 26752109
Drug: Ebastine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine (20 mg/day)
Trial: 12269645
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/day)
Trial: 15178915
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg/day)
Trial: 8206064
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of piperacillin
Trial: 8206064
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of piperacillin
Trial: 2687897
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg bamyphylline
Trial: 26053680
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus a hypocaloric diet for 6 months (group A)
Trial: 20095806
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg glucocorticosteroids for 5 days
Trial: 20095806
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg glucocorticosteroids for 5 days
Trial: 19029466
Drug: torcetrapib/atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: torcetrapib/atorvastatin
Trial: 19029466
Drug: atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin monotherapy
Trial: 1985164
Drug: Parenteral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Parenteral methotrexate (MTX group)
Trial: 6849644
Drug: Amikacin sulfate
RxNorm normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - single dose
Trial: 6849644
Drug: Amikacin sulfate
RxNorm normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - two doses (5 1/2 to 12 hours apart)
Trial: 6849644
Drug: Amikacin sulfate
RxNorm normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin sulfate (7.5 mg/kg, IM) - second dose given 9 to 12 hours after first
Trial: 17440420
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (12 mL/kg)
Trial: 17440420
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (6 mL/kg)
Trial: 27147264
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761® (240 mg daily)
Trial: 23011014
Drug: Generic artemether/lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic artemether/lumefantrine 20/120 mg tablets
Trial: 19414437
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min, group A, n = 13)
Trial: 19414437
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min) and ET‐B receptor blocker BQ‐788 (10 nmol/min, group AB, n = 13)
Trial: 19414437
Drug: ET‐receptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐receptor blockade (both groups)
Trial: 12816266
Drug: Aprotinin (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (30,000 KIU/kg on induction and 10,000 KIU/kg/hr infusion until surgery completion, max 8 hours)
Trial: 8635612
Drug: Ultra-low-dose (75IU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose (75IU) human menopausal gonadotrophin (hMG)
Trial: 1300037
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine (Cim)
Trial: 1300037
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ranitidine (Ran)
Trial: 31892674
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent with laser
Trial: 31892674
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent only
Trial: 31892674
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo prescription)
Trial: 29199720
Drug: Capecitabine (1650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1650 mg/m2 on RT days throughout the course of radiotherapy)
Trial: 29199720
Drug: 5FU (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU (500 mg/m2 on RT days #1‐#5 and #21‐#25)
Trial: 24488721
Drug: Tideglusib 600
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib 600 mg
Trial: 24488721
Drug: Tideglusib 800
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib 800 mg
Trial: 22167570
Drug: Atorvastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (1 mg/kg)
Trial: 22167570
Drug: Rosuvastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (1 mg/kg)
Trial: 22167570
Drug: Simvastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (1 mg/kg)
Trial: 22167570
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and simvastatin in healthy human subjects
Trial: 16189333
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine with midazolam 50 microg x kg(‐1)
Trial: 16189333
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine
Trial: 14621278
Drug: Antisecretory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory factor (AF) treatment as an additive to conventional UC medication
Trial: 12927001
Drug: Sertraline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (up to 100 mg/day)
Trial: 10804075
Drug: Nortriptyline (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (low vs. regular doses)
Trial: 10211012
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg
Trial: 1298491
Drug: Paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg
Trial: 20502743
Drug: Nasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal insulin
Trial: 15288319
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics (10-day course)
Trial: 8479715
Drug: Eye muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye muscle reflectivity measurement in responders to treatment
Trial: 3317344
Drug: Yeast-derived hepatitis
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived hepatitis B vaccine
Trial: 3317344
Drug: Partly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partly purified recombinant vaccines
Trial: 27191766
Drug: Ticagrelor with
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor with moderate CYP3A inhibitors
Trial: 27191766
Drug: Ticagrelor at
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor at treatment initiation (visit 1)
Trial: 17609248
Drug: Remifentanil step‐up/‐down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 0, 2, 6, 2, 0 ng ml(‐1)
Trial: 17609248
Drug: Remifentanil step‐up/‐down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 6, 2, 0, 2, 6 ng ml(‐1)
Trial: 12192713
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of diluted injectable quinimax at a dose of 12.5 mg/kg every 12 hours for 72 hours.
Trial: 12192713
Drug: Intrarectal (IR)
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal (IR) administration of diluted injectable quinimax at a dose of 15 mg/kg every 12 hours for 72 hours.
Trial: 8130028
Drug: Allopurinol (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (1200 mg in two divided doses)
Trial: 2528306
Drug: Mivacurium bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium bolus dose 0.15 mg/kg
Trial: 2528306
Drug: Mivacurium bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium bolus dose 0.25 mg/kg
Trial: 2528306
Drug: Mivacurium bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium bolus dose (both 0.15 mg/kg and 0.25 mg/kg) with no additional mivacurium
Trial: 2528306
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion adjusted to depress twitch response by approximately 95%
Trial: 2528306
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion rates
Trial: 1161344
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (oral sodium bicarbonate treatment when base excess > -8 mEq/liter or suspected acidosis)
Trial: 1161344
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (oral sodium bicarbonate treatment maintaining base excess within 1 SD of normal)
Trial: 1161344
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (oral sodium bicarbonate treatment)
Trial: 1161344
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (oral sodium bicarbonate treatment)
Trial: 25452062
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation medication
Trial: 31816049
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of smoking cessation medications
Trial: 25524432
Drug: Metformin/Sulfonylurea (Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/Sulfonylurea (Control)
Trial: 25524432
Drug: Metformin/Sulfonylurea (Control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/Sulfonylurea (Control, Women)
Trial: 25524432
Drug: Metformin/Sulfonylurea (Control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/Sulfonylurea (Control, Men)
Trial: 21130194
Drug: Pandemic H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic H1N1 vaccine first, followed by seasonal vaccine 21 days later
Trial: 21130194
Drug: Seasonal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal vaccine first, followed by pandemic H1N1 vaccine 21 days later
Trial: 21130194
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines administered simultaneously
Trial: 19943971
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and vigorous intensity exercise
Trial: 17296639
Drug: Long-term targeted
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term targeted therapy
Trial: 16113556
Drug: Betamethasone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (two doses, 24 hours apart)
Trial: 8709687
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg daily, intramuscularly, for three doses)
Trial: 1770216
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 2 gm/day for 30 days
Trial: 6800629
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (oral feeding)
Trial: 28374218
Drug: PAST (treatment-as-usual)
RxNorm normalized name: Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAST (treatment-as-usual)
Trial: 26745346
Drug: Polish treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polish treatment group
Trial: 22782571
Drug: CNE™ low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNE™ low dose (CNE4)
Trial: 22782571
Drug: CNE™ high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNE™ high dose (CNE8)
Trial: 19897418
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus cetuximab (400 mg/m2 initial dose, followed by seven weekly doses at 250 mg/m2)
Trial: 18445258
Drug: Peer-mediated interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peer-mediated interventions (STI/HIV education, condoms, facilitated HIV testing, treatment and care services)
Trial: 10551685
Drug: Thrombolytic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrombolytic administration
Trial: 10520778
Drug: Adjunctive percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery
Trial: 7720766
Drug: FCH-free GTN
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH-free GTN spray with low ethanol content (TL)
Trial: 7720766
Drug: FCH-containing GTN
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH-containing GTN spray (R)
Trial: 7720766
Drug: FCH-free GTN
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH-free GTN spray with higher ethanol content (TH)
Trial: 19627887
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (group 2)
Trial: 9256119
Drug: Idarubicin 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 12 mg/m2/d for 3 days in combination with fludarabine and cytarabine
Trial: 9256119
Drug: Fludarabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and cytarabine (loading dose of 10.5 mg/m2 followed by continuous infusion of 30.5 mg/m2/24 hours for 48 hours, followed by cytarabine loading dose 390 mg/m2, then continuous infusion 101 mg/m2/h for 72 hours)
Trial: 3321925
Drug: 0.75 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 micrograms alpha-calcidol (1 alpha(OH)D3) daily
Trial: 19770753
Drug: Low-dose phospholipid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phospholipid emulsion (850 mg/kg)
Trial: 19770753
Drug: High-dose phospholipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phospholipid emulsion (1350 mg/kg)
Trial: 12616671
Drug: Risperidone 0.5
RxNorm normalized name: risperidone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.5 mg twice daily
Trial: 30109588
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg once daily
Trial: 12616671
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Risperidone 0.5 mg twice daily and Donepezil 5 mg once daily)
Trial: 10883569
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (meditation-relaxation)
Trial: 8256189
Drug: Gentamicin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1.5 mg/kg every 8 hours) plus Mezlocillin (3 grams every 4 hours)
Trial: 3543180
Drug: Oral decongestant-antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral decongestant-antihistamine combination and mucolytic preparation
Trial: 11853215
Drug: Marina (artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marina (artificial mineral water containing K+ and Mg2+ ions), 4 x 200 ml daily for 7 days
Trial: 7915076
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg.kg‐1) followed by vecuronium (0.15 mg.kg‐1)
Trial: 7915076
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no succinylcholine, vecuronium 0.15 mg.kg‐1)
Trial: 7915076
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (supplemental vecuronium 0.04 mg.kg‐1)
Trial: 2656959
Drug: Acetaminophen, 10
RxNorm normalized name: Acetaminophen, 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 10 mg/kg/dose, given at 8 AM, 12 PM, 4 PM, and 8 PM for 4 days.
Trial: 5015033
Drug: Hyoscine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine 0.4 mg
Trial: 5015033
Drug: Hyoscine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine 0.6 mg
Trial: 24421235
Drug: Sequential enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential enteral nutrition (Group A)
Trial: 8913408
Drug: Acarbose in
RxNorm normalized name: Product containing acarbose in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose in combination with sulfonylureas
Trial: 4083302
Drug: 7 P.M.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 P.M. dosing with 800 mg of Uniphyl
Trial: 29557250
Drug: Placebo (saline-soaked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline-soaked gel foam)
Trial: 25357174
Drug: 1,320-nm Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,320-nm Nd:YAG laser treatment